RxDoctor Payments Data

Rebecca Norment, PA

Medical · Paris, TXNPI 1568467165

Payments from drug & device makers

$205in general payments, 2019–2025

Across 12 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$61
  • Inspire Medical Systems, Inc.$31
  • Sanofi-aventis U.S. LLC$29
  • Abbott$21
  • Pfizer$19
  • Novo Nordisk$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$205 in reported general payments places this provider in the 30th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$127,420
Medicare patients
312
Services billed
3,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$63,802
OzempicSemaglutide63$63,675
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$47,237
MounjaroTirzepatide40$40,847
XifaxanRifaximin11$33,343
XareltoRivaroxaban42$27,988
Tresiba Flextouch U-100Insulin Degludec32$21,841
FarxigaDapagliflozin Propanediol26$17,830
Tresiba Flextouch U-200Insulin Degludec27$15,415
JanuviaSitagliptin Phosphate11$14,838
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$14,445
Soliqua 100-33Insulin Glargine/Lixisenatide13$11,763
Breo ElliptaFluticasone/Vilanterol18$11,032
Spiriva RespimatTiotropium Bromide16$10,730
JardianceEmpagliflozin11$10,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$19$70,30999 claims
Novo NordiskOzempic$17$63,67563 claims
Lilly USA, LLCMounjaro$61$40,84740 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$33,34311 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$13$21,34827 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$29$11,76313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,490 medical providers in Texas.

Other medical in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →